May 13, 2020 / 1:11 PM / 24 days ago

BRIEF-Rhythm Pharmaceuticals Gets FDA Acceptance Of New Drug Application For Setmelanotide

May 13 (Reuters) - Rhythm Pharmaceuticals Inc:

* RHYTHM PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR SETMELANOTIDE FOR THE TREATMENT OF POMC AND LEPR DEFICIENCY OBESITIES

* RHYTHM PHARMACEUTICALS INC - FDA GRANTS PRIORITY REVIEW OF APPLICATION AND SETS PDUFA GOAL DATE OF NOVEMBER 27, 2020

* RHYTHM PHARMACEUTICALS - FDA HAS INDICATED THAT IT IS NOT PLANNING AN ADVISORY COMMITTEE MEETING AS PART OF NDA REVIEW Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below